Qvar 80 Patent Expiration

Qvar 80 is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. It is protected by 12 US drug patents filed from 2013 to 2022. Out of these, 8 drug patents are active and 4 have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Jan 01, 2032. Details of Qvar 80's patents and their expiration are given in the table below.

Drug Patent Number Drug Patent Title Drug Patent Expiry Status
These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10561808 Dose counter for inhaler having an anti-reverse rotation actuator
Jan, 2032

(7 years from now)

Active
US10022510 Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

Active
US11395889 Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

Active
US10695512 Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

Active
US10022509 Dose counter for inhaler having a bore and shaft arrangement
May, 2031

(6 years from now)

Active
US9808587 Dose counter for inhaler having an anti-reverse rotation actuator
May, 2031

(6 years from now)

Active
US10086156 Dose counter for inhaler and method for counting doses
May, 2031

(6 years from now)

Active
US9463289 Dose counters for inhalers, inhalers and methods of assembly thereof
May, 2031

(6 years from now)

Active
US6446627 Inhaler dose counter
Dec, 2017

(6 years ago)

Expired
US5776432 Beclomethasone solution aerosol formulations
Jul, 2015

(9 years ago)

Expired
US5683677 Medicinal aerosol formulations
Nov, 2014

(10 years ago)

Expired
US5605674 Medicinal aerosol formulations
Feb, 2014

(10 years ago)

Expired


While patent expiration is one way of estimating the generic date of a drug, if a patent gets invalidated somehow, the generic of the drug may arrive early. Being aware of all relevant patents can help in avoiding legal pitfalls. Given below are details of the litigation history of Qvar 80 and ongoing litigations to help you estimate the early arrival of Qvar 80 generic.

Qvar 80's Litigations

Qvar 80 been subject to various legal proceedings, including patent litigations. The earliest legal proceeding was initiated on Oct 26, 2018, against patent number US10561808. The petitioner , challenged the validity of this patent, with Declan Walsh et al. as the respondent. Click below to track the latest information on how companies are challenging Qvar 80's patents.

Last updated on November 26, 2024
Patent Proceeding Filing Date Status Respondent Petitioner
Patent litigations
US10561808 October, 2018 Decision
(20 Sep, 2019)
Declan Walsh et al.

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

US patents provide insights into the exclusivity only within the United States, but Qvar 80 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Qvar 80's family patents as well as insights into ongoing legal events on those patents.

Qvar 80's Family Patents

Qvar 80 has patent protection in a total of 24 countries. It's US patent count contributes only to 14.3% of its total global patent coverage. 4 countries have all of their patents expired or invalidated which has opened up potential generic launch opportunities in these countries. Click below to unlock the full patent family tree for Qvar 80.

Family Patents

Explore Our Curated Drug Screens

Drugs Generating Over $1 Billion in Annual Revenue
Explore the top-performing drugs that dominate the pharmaceutical industry
View List
NCE-1 Patent Expiry in the Next 1 Year
Identify opportunities as new chemical entity (NCE-1) patents approach expiry
View List
Recently Granted Patents in EP
Find the opportunity to file Oppositions
View List


Generic Launch

Generic Release Date:

Qvar 80's generic launch date based on the expiry of its last outstanding patent is estimated to be Jan 01, 2032 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)

Qvar 80 Generics:

There are no approved generic versions for Qvar 80 as of now.

How can I launch a generic of Qvar 80 before its drug patent expiration? :

You can seek FDA approval to launch a generic drug before the expiration of Qvar 80's patents related by providing a 'paragraph IV certification' in your application, which states that the patent submitted by the Qvar 80's sponsor is invalid, unenforceable, or will not be infringed by your generic product.

Given below are the details of the already filed Para IV certificates on Qvar 80 -

Strength Submission Date ANDA(s) Filed First applicant approval Last patent expiry 180 day status
40 mcg/actuation and 80 mcg/actuation 10 Jan, 2020 1 18 May, 2031

Alternative Brands for Qvar 80

There are several other brand drugs using the same active ingredient (Beclomethasone Dipropionate) as Qvar 80. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.

Drug Owner Drug Name
Norton Waterford
Qvar Redihaler
Teva Branded Pharm
Qnasl
Qvar 40






About Qvar 80

Qvar 80 is a drug owned by Teva Branded Pharmaceutical Products R And D Inc. Qvar 80 uses Beclomethasone Dipropionate as an active ingredient. Qvar 80 was launched by Teva Branded Pharm in 2000.

Approval Date:

Qvar 80 was approved by FDA for market use on 15 September, 2000.

Active Ingredient:

Qvar 80 uses Beclomethasone Dipropionate as the active ingredient. Check out other Drugs and Companies using Beclomethasone Dipropionate ingredient

Dosage:

Qvar 80 is available in aerosol, metered form for inhalation use. Given below is detailed information on Dosage -

Strength Dosage Form Availability Application Pathway
0.08MG/INH **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** AEROSOL, METERED Discontinued INHALATION